T. Henley

A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine

This paper describes a CRISPR-engineered cellular vaccine designed to mimic natural immunity, showing robust neutralizing antibody responses and reduced viral load in non-human primates.

Homology mediated end joining enables efficient non-viral targeted integration of large DNA templates in primary human T cells

This paper describes a non-viral method for efficiently integrating large DNA into primary human T cells using CRISPR-Cas9 and homology-mediated end joining, achieving high functionality and anti-tumor activity.

Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression

This study shows that genetic editing of CISH enhances T cell anti-tumor activity independently of PD-L1 expression, outperforming PD-1 and TIGIT disruption in certain contexts.

A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)

This paper describes a method to generate virus-specific T cells from convalescent patients using artificial antigen presenting cells and rapid expansion, showing their potential as an adoptive cell therapy for COVID-19 and other viral infections.

AAV Capsid Chimeras with Enhanced Infectivity reveal a core element in the AAV Genome critical for both Cell Transduction and Capsid Assembly

This paper develops an AAV chimera, AAV-XV, with enhanced T cell transduction efficiency at lower doses and identifies a critical genomic region for both capsid assembly and transduction.

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

This study shows that CISH knockout in TIL enhances neoantigen reactivity and synergizes with PD1 blockade to improve tumor regression.